生物医药控股 BHVN 深 沪
等待开盘 01-29 09:30:00 美东时间
12.23
-0.440
-3.47%
华盛通- 最 高12.90
- 今 开12.83
- 成交量 61.73万股
- 最 低 12.125
- 昨 收 12.67
- 总市值 12.47亿
- 52周最高 44.2803
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 7.48
- 委 比 -25.71%
- 总股本 1.02亿
- 历史最高 152.56
- 量 比 0.33
- 振 幅 6.12%
- 历史最低 7.10
- 每 手 1
- 风险率 8.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
RBC Capital Upgrades Biohaven to Outperform, Raises Price Target to $22
RBC Capital analyst Leonid Timashev upgrades Biohaven (NYSE:BHVN) from Sector Perform to Outperform and raises the price target from $9 to $22.
01-21 18:58
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know
Biohaven Ltd. shares surged 3.42% in after-hours trading following an SEC filing that detailed investor presentations and updates on its drug pipeline.
01-15 10:48
Biohaven highlights degrader platforms in new investor presentation
The latest announcement is out from Biohaven Ltd. ( ($BHVN) ). On January 12, 2...
01-13 00:48
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $21
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers the price target from $26 to $21.
01-06 23:25
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gainin...
01-02 21:02
美股大行评级 | 潜在涨幅121.27%！HC Wainwright & Co.：Agios Pharmaceuticals获机构升目标价至62美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Agios Pharmaceuticals"买入"评级，目标价从48美元升至62美元；Leerink Partners：维持Agios Pharmaceuticals"跑赢大市"评级，目标价从34美元升至40美元
2025-12-29 10:27
What's Going On With Biohaven Stock Friday?
Biohaven shares are flat after the company announced its Phase 2 proof-of-concept study of BHV-7000 failed to meet its primary-endpoint.
2025-12-27 02:12
Biohaven Announces Its Phase 2 Trial Of BHV-7000 To Treat Major Depressive Disorder Failed To Meet Primary Endpoint As Measured By Change In Montgomery Asberg Depression Rating Scale Over Six Weeks With Placebo
Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common
2025-12-25 02:02
